706 related articles for article (PubMed ID: 10344749)
1. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
[TBL] [Abstract][Full Text] [Related]
3. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
4. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
8. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
9. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
13. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
Evans AE; Kisselbach KD; Liu X; Eggert A; Ikegaki N; Camoratto AM; Dionne C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):181-4. PubMed ID: 11464878
[TBL] [Abstract][Full Text] [Related]
14. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
15. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
Delsite R; Djakiew D
J Androl; 1996; 17(5):481-90. PubMed ID: 8957691
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
Evans AE; Kisselbach KD; Yamashiro DJ; Ikegaki N; Camoratto AM; Dionne CA; Brodeur GM
Clin Cancer Res; 1999 Nov; 5(11):3594-602. PubMed ID: 10589776
[TBL] [Abstract][Full Text] [Related]
19. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
20. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
Pinski J; Weeraratna A; Uzgare AR; Arnold JT; Denmeade SR; Isaacs JT
Cancer Res; 2002 Feb; 62(4):986-9. PubMed ID: 11861369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
